选择性EGFR酪氨酸激酶抑制剂(EGFR-TKI)是非小细胞肺癌靶向治疗的代表性药物。对于既往接受过多周期化疗而病情难以控制的ⅢB～Ⅳ期肺腺癌患者,EGFR-TKI是治疗的首选。随着分子生物学的研究进展,越来越多的基因组学标志物用于预测靶向治疗的效果。 Selective EGFR tyrosine kinase inhibitor (EGFR-TKI) is a representative drug for targeted therapy in non-small cell lung cancer. EGFR-TKI is the treatment of choice for patients with stage ⅢB-Ⅳ lung adenocarcinoma who have previously received chemotherapy for multiple cycles and whose condition is difficult to control. With the development of molecular biology, more and more genomic markers are used to predict the effect of targeted therapy.